{"product_id":"fda-form-483-esperion-therapeutics-inc-samer-kazziha-md","title":"FDA Form 483 – Esperion Therapeutics Inc (Samer Kazziha, MD)","description":"\u003cb\u003eOriginal Request:\u003c\/b\u003e  Request 483 information for Samer Kazziha, MD, Cardiovascular Consultants, PC Esperion Therapeutics Inc, Protocol # 1002-043 Title of Project: A randomized double-blind, placebo-controlled study to assess the effects of Bempedoic Acid (ETC=1002) on the occurrence of major cardiovasular events in patient with, or at high risk for, cardiovascular disease who are statin intolerant. Thank you.","brand":"FDA","offers":[{"title":"Default Title","offer_id":50860942917796,"sku":"FDAFT839","price":89.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/foiadocs.com\/products\/fda-form-483-esperion-therapeutics-inc-samer-kazziha-md","provider":"FOIA Document Source","version":"1.0","type":"link"}